London-based Briefly Bio launches with $1.2m pre-seed funding to address $50bn annual reproducibility crisis in preclinical research, using AI to standardize experiment descriptions.
London-based techbio startup Briefly Bio has launched with a $1.2m pre-seed funding round to tackle the reproducibility crisis in preclinical research. Over 50% of experiments in this field fail to be reproduced, costing the industry over $50bn annually. Briefly Bio's software aims to improve lab work reproducibility by helping scientists capture and share their work clearly and consistently, using AI to convert existing experiment descriptions into a consistent format.
July 17, 2024
4 Articles